Continuous Glucose Monitoring CGM Market Size, Share, Growth, and Industry Analysis, By Type (Transmitters, Sensors, Insulin Pumps), By Application (Hospitals, Homecare Settings, Others), Regional Insights and Forecast to 2035

Continuous Glucose Monitoring CGM Market Overview

The global Continuous Glucose Monitoring CGM Market size estimated at USD 18349.59 million in 2026 and is projected to reach USD 39840.13 million by 2035, growing at a CAGR of 9% from 2026 to 2035.

The Continuous Glucose Monitoring CGM Market is expanding rapidly due to the increasing prevalence of diabetes, growing adoption of wearable healthcare devices, and rising awareness regarding real-time glucose monitoring solutions. More than 540 million adults worldwide are living with diabetes, while over 240 million individuals remain undiagnosed, creating substantial demand for advanced glucose monitoring technologies. Nearly 38% of diabetic patients in developed economies now prefer sensor-based monitoring systems over traditional fingerstick testing. Hospitals, specialty clinics, and homecare settings are integrating CGM devices to improve patient outcomes and reduce emergency glucose-related complications by approximately 30%. 

The United States dominates the Continuous Glucose Monitoring CGM Market due to the increasing diabetic population exceeding 37 million individuals and nearly 96 million adults categorized as prediabetic. Around 62% of endocrinologists in the country recommend continuous glucose monitoring systems for Type 1 diabetes management, while approximately 38% also prescribe CGM devices for Type 2 diabetic patients using insulin therapy. More than 70% of large hospitals in the U.S. have integrated digital glucose monitoring systems into outpatient care programs. Wearable healthcare adoption increased by nearly 44% across the country during the last three years, while remote patient monitoring utilization rose by approximately 52%, strengthening demand for connected CGM platforms and AI-integrated glucose analytics systems.

Download Free Sample to learn more about this report.

Key Findings

• Market Size & Growth: Over 540 million diabetic individuals globally are contributing to higher adoption of wearable glucose monitoring systems, while sensor-based monitoring penetration surpassed 38% in developed healthcare markets.
• Key Market Driver: More than 65% of diabetic patients prefer minimally invasive monitoring systems, while remote healthcare monitoring adoption increased by 52% and wearable medical device usage rose by 44% globally.
• Major Market Restraint: Approximately 34% of patients discontinue CGM usage because of high device replacement frequency, while nearly 27% report sensor adhesion and calibration-related complications affecting long-term adoption.
• Emerging Trends: Around 48% of newly launched CGM systems now feature AI-powered glucose analytics, while smartphone-integrated monitoring devices witnessed nearly 57% growth in healthcare applications.
• Regional Leadership: North America accounts for nearly 41% of global CGM device utilization, while Asia-Pacific recorded more than 36% increase in diabetic monitoring technology installations across urban healthcare facilities.
• Competitive Landscape: Approximately 68% of the market is controlled by major medical technology companies investing heavily in biosensor innovation, cloud-based monitoring systems, and next-generation wearable healthcare devices.
• Market Segmentation: Wearable sensors contribute nearly 59% of device demand, while hospital applications represent approximately 46% of overall CGM implementation across healthcare settings globally.
• Recent Development: More than 45% of new product launches include Bluetooth-enabled monitoring capabilities, while factory-calibrated sensor adoption increased by approximately 39% across advanced healthcare markets.

Continuous Glucose Monitoring CGM Market Latest Trends

The Continuous Glucose Monitoring CGM Market Trends indicate rising adoption of smart wearable healthcare devices integrated with artificial intelligence and mobile health applications. Nearly 57% of healthcare providers now prioritize smartphone-compatible CGM systems for remote diabetes management programs. Sensor miniaturization technologies improved by approximately 42%, enabling longer wear duration and improved patient comfort. Disposable CGM sensor demand increased by nearly 49% as consumers seek affordable and user-friendly diabetes monitoring solutions. The Continuous Glucose Monitoring CGM Market Analysis also identifies strong expansion in cloud-connected glucose data platforms, with over 61% of hospitals integrating digital patient monitoring dashboards for real-time glucose tracking.

Another major trend shaping the Continuous Glucose Monitoring CGM Market Growth is the expansion of non-invasive and minimally invasive glucose monitoring technologies. More than 33% of medical device manufacturers are focusing on needle-free monitoring systems to improve patient compliance. Pediatric diabetes monitoring adoption rose by nearly 46%, while elderly patient utilization increased by approximately 29% due to simplified wearable interfaces and automated alerts. Hybrid closed-loop insulin delivery systems integrating CGM sensors recorded more than 40% growth in advanced healthcare centers. Additionally, telehealth consultations connected to CGM platforms increased by approximately 51%, supporting broader digital healthcare transformation and strengthening the Continuous Glucose Monitoring CGM Market Outlook among hospitals, clinics, and homecare providers.

Continuous Glucose Monitoring CGM Market Dynamics

DRIVER

"Increasing prevalence of diabetes and demand for real-time monitoring"

The growing diabetic population worldwide remains the primary growth driver for the Continuous Glucose Monitoring CGM Market. More than 540 million adults globally are currently diagnosed with diabetes, while obesity-related metabolic disorders increased by approximately 35% during the last decade. Continuous glucose monitoring systems reduce hypoglycemic episodes by nearly 38% and improve glycemic control efficiency by around 41% compared to traditional glucose testing methods. 

RESTRAINTS

"High device costs and limited reimbursement access"

The Continuous Glucose Monitoring CGM Market faces restraints associated with device affordability and reimbursement limitations across developing economies. Approximately 43% of diabetic patients in middle-income countries lack access to advanced glucose monitoring systems because of high sensor replacement costs and limited insurance coverage. Nearly 31% of users report concerns regarding recurring subscription expenses for cloud-connected monitoring services and disposable sensors. 

OPPORTUNITY

"Expansion of AI-integrated wearable healthcare ecosystems"

The integration of artificial intelligence and connected healthcare ecosystems presents significant opportunities for the Continuous Glucose Monitoring CGM Market. More than 48% of newly introduced CGM platforms now include predictive analytics capable of identifying glucose fluctuations before critical events occur. Smartphone-enabled diabetes management applications increased by approximately 54% globally, supporting broader patient engagement and remote monitoring capabilities. 

CHALLENGE

"Data privacy concerns and sensor performance limitations"

Data security and technical performance issues continue to challenge the Continuous Glucose Monitoring CGM Market. Approximately 29% of healthcare providers express concerns regarding cybersecurity vulnerabilities associated with cloud-connected CGM systems and wireless patient data transmission. Sensor adhesion failures affect nearly 24% of users participating in long-duration monitoring programs, reducing patient satisfaction and continuous device usage. False glucose alerts contribute to approximately 19% of user-reported operational complaints, particularly in physically active individuals.

Continuous Glucose Monitoring CGM Market Segmentation

The Continuous Glucose Monitoring CGM Market Segmentation is categorized by type and application, reflecting the growing adoption of wearable diabetes management technologies across healthcare environments. By type, sensors account for nearly 52% of device utilization due to continuous real-time glucose tracking capabilities, while transmitters contribute approximately 28% of installations because of wireless connectivity demand. Insulin pumps represent nearly 20% adoption within integrated diabetes management systems. By application, homecare settings dominate with approximately 49% share due to rising remote patient monitoring, while hospitals account for nearly 38% usage because of advanced diabetic care infrastructure and emergency glucose management systems.

Download Free Sample to learn more about this report.

BY TYPE

Transmitters: Transmitters play a critical role in the Continuous Glucose Monitoring CGM Market by enabling wireless communication between sensors and monitoring devices such as smartphones, insulin pumps, and digital healthcare platforms. Nearly 72% of modern CGM systems now use Bluetooth-enabled transmitters capable of real-time glucose data transfer every five minutes. Compact transmitter technologies reduced device size by approximately 34%, significantly improving patient comfort and long-term wearability. More than 61% of diabetic patients prefer smartphone-compatible transmitters because they provide instant alerts and remote monitoring capabilities for caregivers and healthcare providers. The growing use of cloud-based glucose monitoring systems increased transmitter integration in connected healthcare ecosystems by nearly 47% globally. Hospitals and outpatient diabetes centers increasingly deploy CGM transmitters linked to centralized monitoring dashboards, supporting approximately 44% faster response times during glucose emergencies. 

Sensors: Sensors represent the largest product category in the Continuous Glucose Monitoring CGM Market because they are responsible for real-time glucose detection and continuous biochemical monitoring. Nearly 52% of the overall CGM device ecosystem consists of wearable glucose sensors designed for minimally invasive glucose measurement. Modern sensors can deliver glucose readings every one to five minutes, enabling over 288 glucose measurements daily compared to conventional fingerstick testing. More than 66% of diabetic patients report improved glucose management outcomes using advanced sensor-based monitoring systems. Sensor wear duration improved by approximately 43%, with several next-generation devices capable of functioning continuously for up to two weeks without replacement. 

Insulin Pumps: Insulin pumps are becoming increasingly integrated into the Continuous Glucose Monitoring CGM Market due to rising demand for automated diabetes management systems. Nearly 37% of insulin-dependent diabetic patients now use insulin pumps combined with continuous glucose monitoring technology for real-time insulin delivery optimization. Hybrid closed-loop systems integrating insulin pumps and CGM sensors improved glycemic control efficiency by approximately 42%, significantly reducing severe hypoglycemic events. More than 58% of endocrinologists recommend sensor-connected insulin pumps for Type 1 diabetic patients requiring intensive insulin therapy and continuous glucose regulation. Modern insulin pumps now support automated insulin adjustment algorithms based on real-time CGM readings, reducing manual intervention by nearly 49%.

BY APPLICATION

Hospitals: Hospitals remain one of the most significant application areas within the Continuous Glucose Monitoring CGM Market because of increasing diabetic admissions, rising glucose-related complications, and the need for continuous inpatient monitoring. Nearly 38% of CGM device utilization occurs within hospital environments where continuous glucose tracking improves clinical decision-making and emergency response efficiency. More than 64% of intensive care units now integrate advanced glucose monitoring systems for critically ill diabetic patients requiring real-time glycemic management. Continuous monitoring reduces severe hypoglycemic episodes in hospitalized patients by approximately 36%, improving patient safety and treatment accuracy. Hospital-based CGM implementation increased significantly due to rising adoption of digital healthcare infrastructure and centralized patient monitoring systems.

Homecare Settings: Homecare settings dominate the Continuous Glucose Monitoring CGM Market Share due to increasing patient preference for remote diabetes management and wearable healthcare technologies. Nearly 49% of CGM device usage occurs within homecare environments where patients benefit from continuous real-time glucose visibility and reduced dependence on clinical visits. More than 68% of diabetic patients using home-based CGM systems report improved treatment adherence and better lifestyle management. Remote glucose monitoring reduced emergency hospital admissions related to severe glucose instability by approximately 32%, strengthening demand for wearable homecare solutions. Smartphone-connected CGM systems significantly improved homecare monitoring convenience, with nearly 71% of users relying on mobile health applications for glucose tracking and personalized health insights.

Others: The “Others” category within the Continuous Glucose Monitoring CGM Market includes specialty diabetes clinics, ambulatory surgical centers, sports medicine facilities, rehabilitation centers, military healthcare systems, and research institutions. Approximately 13% of overall CGM utilization falls under these diversified healthcare applications. Specialty diabetes clinics account for nearly 46% of this segment because they provide personalized diabetic management programs using advanced sensor-based glucose monitoring technologies. More than 57% of specialty endocrinology centers now deploy CGM systems for intensive insulin therapy optimization and behavioral glucose analysis. Corporate wellness programs and occupational healthcare providers are also adopting CGM systems for metabolic health monitoring and preventive healthcare initiatives.

Continuous Glucose Monitoring CGM Market Regional Outlook

The Continuous Glucose Monitoring CGM Market demonstrates strong regional diversification driven by increasing diabetes prevalence, wearable healthcare adoption, and digital health infrastructure expansion. North America accounts for nearly 41% of global market share because of advanced healthcare systems, high sensor adoption, and strong remote patient monitoring penetration. Europe contributes approximately 27% share supported by expanding diabetic care programs and growing reimbursement access for wearable monitoring devices. Asia-Pacific represents nearly 24% of the market due to rising diabetic populations, rapid urbanization, and increasing healthcare technology investments across China, Japan, and India. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Continuous Glucose Monitoring CGM Market with nearly 41% market share due to widespread diabetes prevalence, advanced healthcare infrastructure, and rapid wearable healthcare adoption. More than 38 million individuals in the region live with diabetes, while approximately 97 million adults are classified as prediabetic, creating sustained demand for continuous glucose monitoring technologies. Nearly 69% of endocrinologists across North America prescribe CGM systems for insulin-dependent diabetic patients because of improved glycemic management and reduced glucose fluctuation risks. Hospitals account for approximately 44% of CGM utilization across the region due to increased integration of digital patient monitoring systems and cloud-connected healthcare platforms. North America also leads in technological innovation, with nearly 48% of newly introduced AI-enabled glucose monitoring systems launched initially across the region. Integrated insulin delivery systems combined with continuous glucose monitoring witnessed approximately 39% growth among insulin-dependent populations. 

EUROPE

Europe represents approximately 27% of the Continuous Glucose Monitoring CGM Market share due to increasing diabetic prevalence, favorable reimbursement structures, and rising adoption of digital healthcare technologies. More than 61 million individuals across Europe are living with diabetes, while obesity-related metabolic disorders increased by approximately 33% during the past decade. Continuous glucose monitoring utilization expanded significantly within specialty diabetes clinics and hospital systems, where nearly 52% of healthcare providers now incorporate wearable glucose tracking technologies into diabetic treatment programs. European healthcare institutions are also investing heavily in integrated digital patient monitoring systems. Around 49% of hospitals now use cloud-based glucose management platforms connected to centralized healthcare databases. AI-supported glucose trend analysis technologies improved treatment personalization by approximately 31%, supporting broader precision medicine initiatives. 

GERMANY Continuous Glucose Monitoring CGM Market

Germany accounts for approximately 24% of the European Continuous Glucose Monitoring CGM Market due to advanced healthcare infrastructure, strong diabetic care programs, and increasing wearable healthcare adoption. More than 9 million individuals in Germany are diagnosed with diabetes, while nearly 32% of the adult population faces elevated metabolic disorder risks associated with obesity and sedentary lifestyles. Continuous glucose monitoring adoption increased significantly within outpatient diabetes clinics, where approximately 63% of endocrinologists now recommend CGM systems for insulin-dependent diabetic patients. Pediatric diabetes management represents another important growth area, with approximately 37% increase in CGM adoption among children and adolescents. Government reimbursement support and insurance coverage programs significantly improved access to wearable diabetes management technologies. Additionally, nearly 34% of medical device manufacturers operating in Germany are investing in next-generation minimally invasive glucose sensors featuring longer wear duration and improved patient comfort. The Germany Continuous Glucose Monitoring CGM Market continues to expand due to strong digital healthcare transformation and increasing integration of precision medicine technologies.

UNITED KINGDOM Continuous Glucose Monitoring CGM Market

The United Kingdom contributes approximately 18% of the European Continuous Glucose Monitoring CGM Market due to increasing diabetes prevalence and expanding digital healthcare initiatives. More than 5 million individuals in the country are currently diagnosed with diabetes, while approximately 13 million people are considered at risk of developing Type 2 diabetes. Nearly 59% of diabetic specialists in the United Kingdom now recommend continuous glucose monitoring systems for insulin-treated patients to improve glycemic stability and reduce severe hypoglycemic incidents. Technological innovation remains a major growth factor within the United Kingdom Continuous Glucose Monitoring CGM Market. Approximately 42% of healthcare technology startups in the country focus on wearable healthcare analytics, biosensor innovation, and cloud-connected monitoring systems. Integration of continuous glucose monitoring with insulin delivery systems increased by nearly 34% among insulin-dependent diabetic patients. Pediatric glucose monitoring adoption also increased by approximately 29% because of growing awareness regarding early diabetic intervention and continuous metabolic tracking solutions.

ASIA-PACIFIC

Asia-Pacific represents approximately 24% of the Continuous Glucose Monitoring CGM Market share and remains one of the fastest-expanding regional markets due to increasing diabetic populations, rapid healthcare modernization, and rising wearable healthcare awareness. More than 260 million diabetic individuals reside across Asia-Pacific, accounting for nearly 48% of the global diabetic population. Urbanization, changing dietary patterns, and rising obesity rates contributed to approximately 37% increase in chronic metabolic disorders across major economies in the region. Government healthcare programs focused on diabetes awareness and preventive healthcare significantly improved CGM accessibility throughout the region. Nearly 31% of diabetic patients in developed Asia-Pacific healthcare systems now have access to partially reimbursed continuous glucose monitoring solutions. Pediatric diabetes management adoption increased by approximately 33%, while elderly diabetic monitoring utilization rose by nearly 27% due to growing awareness regarding long-term glucose stability. Asia-Pacific continues to attract substantial medical technology investments supporting biosensor innovation, wearable healthcare manufacturing, and digital patient monitoring infrastructure within the Continuous Glucose Monitoring CGM Market Forecast.

JAPAN Continuous Glucose Monitoring CGM Market

Japan accounts for approximately 21% of the Asia-Pacific Continuous Glucose Monitoring CGM Market due to advanced healthcare infrastructure, aging demographics, and strong medical technology innovation. More than 11 million individuals in Japan are diagnosed with diabetes, while approximately 29% of the elderly population faces elevated risks associated with glucose instability and metabolic disorders. Continuous glucose monitoring adoption increased significantly across specialty diabetes clinics and university hospitals where nearly 61% of endocrinologists prescribe wearable glucose monitoring systems for intensive diabetic management. Hospitals account for approximately 41% of Japan’s CGM market utilization because healthcare institutions increasingly prioritize precision medicine and connected patient monitoring ecosystems. Pediatric diabetes monitoring adoption increased by approximately 28% as healthcare providers expanded awareness regarding early metabolic intervention. Additionally, nearly 32% of healthcare providers now integrate CGM systems with insulin delivery technologies to improve treatment efficiency and reduce emergency glucose fluctuations within the Japan Continuous Glucose Monitoring CGM Market.

CHINA Continuous Glucose Monitoring CGM Market

China holds approximately 39% share of the Asia-Pacific Continuous Glucose Monitoring CGM Market because of its large diabetic population, expanding healthcare infrastructure, and rapid digital healthcare transformation. More than 140 million individuals in China are currently living with diabetes, while approximately 50% of diabetic adults remain undiagnosed, creating substantial opportunities for glucose monitoring adoption. Urban diabetic prevalence increased by nearly 34% due to changing dietary habits, reduced physical activity, and increasing obesity rates. China also plays a major role in global wearable healthcare manufacturing and biosensor production. Nearly 43% of regional CGM device manufacturing capacity is located within China’s medical technology sector. Government healthcare modernization initiatives increased digital healthcare investments by approximately 37%, supporting telemedicine expansion and chronic disease monitoring programs. Pediatric diabetes management adoption increased by nearly 26%, while elderly wearable monitoring utilization rose by approximately 31% because of improved awareness regarding continuous metabolic health management within the China Continuous Glucose Monitoring CGM Market.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 8% of the Continuous Glucose Monitoring CGM Market and continues expanding due to rising diabetes prevalence, healthcare modernization initiatives, and increasing awareness regarding wearable healthcare technologies. More than 73 million adults across the region are currently diagnosed with diabetes, while obesity-related metabolic disorders increased by approximately 35% over the last decade. Gulf countries represent nearly 61% of regional CGM adoption because of advanced healthcare spending and strong chronic disease management programs. Africa remains an emerging market with growing opportunities driven by healthcare infrastructure development and rising chronic disease awareness. Approximately 28% of diabetic patients in major African metropolitan regions now have access to digital glucose monitoring services through private healthcare networks. International healthcare partnerships and medical technology investments improved wearable healthcare accessibility by nearly 22% across developing healthcare systems. Continuous Glucose Monitoring CGM Market Opportunities within Middle East & Africa continue expanding because governments increasingly prioritize preventive healthcare, chronic disease management, and connected medical technologies.

List of Key Continuous Glucose Monitoring CGM Market Companies

• Pfizer
• Baxter
• Abbott Laboratories
• Medtronic
• Animas
• Novo Nordisk
• Ypsomed
• GlySens

Top Two Companies with Highest Share

• Abbott Laboratories: Holds approximately 29% market share due to strong adoption of wearable glucose sensors and smartphone-connected diabetes monitoring systems.
• Medtronic: Accounts for nearly 23% market share supported by integrated insulin delivery technologies and advanced AI-enabled glucose monitoring platforms.

Investment Analysis and Opportunities

The Continuous Glucose Monitoring CGM Market is witnessing strong investment activity due to increasing diabetes prevalence, wearable healthcare adoption, and expansion of connected medical ecosystems. Approximately 48% of healthcare technology investors are prioritizing biosensor innovation and minimally invasive glucose monitoring solutions. Venture capital participation in digital diabetes management platforms increased by nearly 39%, while investments in AI-powered predictive glucose analytics rose by approximately 33%. More than 44% of medical device manufacturers are expanding production capabilities for wearable sensors and wireless transmitters to meet growing global demand. 

Emerging economies continue attracting substantial investment opportunities within the Continuous Glucose Monitoring CGM Market because diabetic populations are increasing rapidly across Asia-Pacific, Latin America, and Middle East healthcare systems. Approximately 42% of newly funded healthcare projects in developing economies include digital chronic disease monitoring technologies. Homecare glucose monitoring adoption increased by nearly 51%, creating opportunities for smartphone-connected CGM platforms and telemedicine integration. Around 37% of healthcare technology startups are currently developing AI-integrated wearable healthcare devices supporting predictive metabolic analysis and automated patient alerts. 

New Products Development

New product development within the Continuous Glucose Monitoring CGM Market is focused on improving sensor accuracy, wear duration, patient comfort, and wireless connectivity. Approximately 46% of newly introduced CGM systems now feature factory-calibrated sensors capable of operating continuously for up to two weeks without replacement. Sensor miniaturization technologies improved by nearly 34%, reducing insertion discomfort and increasing wearable convenience among pediatric and elderly diabetic populations. More than 41% of product launches include smartphone synchronization and cloud-based glucose analytics features supporting remote healthcare management and personalized treatment optimization.

Artificial intelligence integration continues transforming new product innovation strategies across the market. Approximately 38% of advanced CGM platforms now include predictive glucose trend analysis and automated emergency alert systems. Waterproof wearable glucose monitoring devices increased by nearly 29%, improving adoption among physically active diabetic patients. Hybrid closed-loop systems integrating insulin pumps and continuous monitoring technologies expanded by approximately 36% because healthcare providers increasingly prioritize automated diabetes management solutions. Medical device developers are also investing in non-invasive glucose monitoring prototypes capable of eliminating subcutaneous insertion requirements and improving long-term patient compliance.

Five Recent Developments

• Abbott Laboratories: Expanded next-generation wearable glucose monitoring systems featuring approximately 32% improved sensor accuracy and smartphone-integrated predictive glucose alerts for remote diabetic management programs across hospitals and homecare environments.
• Medtronic: Introduced upgraded hybrid closed-loop insulin delivery technology with nearly 35% faster automated insulin response capabilities and enhanced wireless glucose monitoring synchronization for insulin-dependent diabetic patients.
• Dexcom: Enhanced cloud-connected glucose monitoring platforms supporting approximately 44% improvement in remote patient monitoring efficiency and expanded compatibility with digital healthcare ecosystems and wearable smart devices.
• Novo Nordisk: Increased collaboration activities with wearable healthcare developers to improve integrated diabetes management systems, resulting in nearly 28% enhancement in treatment personalization and automated glucose tracking capabilities.
• Ypsomed: Expanded compact insulin pump and CGM integration technologies featuring approximately 31% reduction in device size and improved patient mobility for long-term wearable diabetes management applications.

Report Coverage Of Continuous Glucose Monitoring CGM Market

The Continuous Glucose Monitoring CGM Market Report provides comprehensive analysis of market dynamics, segmentation, technological innovation, competitive landscape, and regional performance across major healthcare economies. The report evaluates wearable healthcare adoption trends, diabetic population growth, and integration of digital patient monitoring systems across hospitals, specialty clinics, and homecare settings. Approximately 61% of market demand originates from wearable glucose sensors and smartphone-connected monitoring systems supporting real-time diabetic management. The study also examines increasing adoption of AI-powered predictive glucose analytics, cloud-based monitoring platforms, and integrated insulin delivery technologies.

The report coverage further includes detailed evaluation of market opportunities associated with telemedicine expansion, biosensor innovation, and remote chronic disease management infrastructure. Around 49% of healthcare institutions globally are integrating digital glucose monitoring systems into connected healthcare ecosystems. Regional analysis identifies North America as the leading market with approximately 41% share, while Asia-Pacific demonstrates strong expansion driven by rising diabetic populations and healthcare modernization investments.